Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
about
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainMolecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and CoevolutionBCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.A bead-based activity screen for small-molecule inhibitors of signal transduction in chronic myelogenous leukemia cells.PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinasesAn update on dual Src/Abl inhibitors.Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.BAY 43-9006 inhibition of oncogenic RET mutants.Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.Tyrosine kinase inhibitors: Multi-targeted or single-targeted?Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitorsThe ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profilePD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemiaInhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesisTargeted therapy for hematologic malignancies.Src kinase signaling in leukaemiaPersonalized medical treatment strategies for patients with chronic myeloid leukemia.A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemiaDual tyrosine kinase inhibitors in chronic myeloid leukemia.Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics.FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.The new paradigm in the treatment of colorectal cancer: are we hitting the right target?Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative diseaseCurrent status of therapy for chronic myeloid leukemia: a review of drug development.Imatinib mesylate for the treatment of chronic myeloid leukemia.NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor.Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib.Current status of agents active against the T315I chronic myeloid leukemia phenotype.Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells.Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives.Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases.BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.
P2860
Q24648017-1C63430D-C904-4D7F-A81B-6D175220A125Q24794765-D9BE16BC-2B50-47E1-B38C-8F1B50040318Q28548366-C5F16A66-A50B-42A8-B80B-E5D7E0F111D7Q30156840-A513C476-493B-40F5-B600-966B784EF8A9Q30981853-B4324FDC-6DF4-425F-B8E3-4ECA41512965Q33779210-A3B2887F-D680-4C1C-B3F3-9DD2561D2255Q33906140-69A793A0-0B27-4B0F-B736-8007C8BB5880Q34270677-94428E18-65B6-4699-AEC8-245B92E9F87BQ34525925-1E0A716D-7C48-4780-92D5-EFFEA26FB601Q34565246-103E819D-11C9-4421-9861-DBEBC8E9374DQ34695008-CADA4B98-A858-4224-BB84-1ACAE01F948CQ34983846-E1F95D0A-8A3D-44E3-887E-EE4DA67A55A1Q35119075-5FB1C934-BBF8-4674-A07B-D61CF1B1BF46Q35459748-BAA9CA33-5904-4AE6-B2D0-D1A97FCBEE9BQ35506849-FA9EDC30-3436-4A15-BE96-0AF42D4D101CQ35847727-1F19881F-D48B-4EC1-A39F-E73A8F226473Q35847734-0F92D7D9-AA46-4B0F-9A01-39D41265E990Q35852817-4B08CD45-2364-4DFA-A48B-4E8CD0134365Q35900937-44674061-3109-49E2-8F12-764ADCD57AC2Q36007575-D3717551-BFDA-4B9D-BBC6-FDA75B17E3CBQ36108610-FAE2E6AE-F507-4C52-97FD-B48D3C095FB7Q36116937-F079718C-0049-495A-9E3D-23B436040DC0Q36118424-70BE7F95-18C8-41A4-B679-41D05B3D3DA4Q36210636-18047EFA-B2E9-456F-ABE9-D608A76229CAQ36265601-F2122B84-2AC6-4F59-B16A-4D71601C58E8Q36300062-8B5D9E7C-3A5C-4331-9ADB-FDF858EAF96CQ36334327-317A28FB-9041-48D8-B06A-77B304C884E5Q36535476-BD686FDD-8D1E-4C74-BFD1-868DDF5372B7Q36736346-D7F29650-6525-42CA-9722-A316AC511735Q36758024-43BED2F7-E8B6-401D-9B4D-57934733D4ADQ36843762-20F116D3-FCB0-4FDA-9CA0-1288410E4AFAQ37179388-132C086A-6C55-4D4C-A0B5-CA38FA15E920Q37183434-41D64C24-9DCA-4DF9-BED6-97E10D90DD9BQ37574957-CCEA8A89-110F-4984-A07A-40E02B49E34BQ37771246-51E124FC-B116-4642-AEB0-2E5C7A2805BEQ37847179-4D93A52A-F17D-43E4-BA81-26772EBFF314Q38719813-D94B9235-4398-4824-8D22-2D7F019F2BF4Q38739574-206D4C61-1BAC-4855-9D67-061D1CA10569Q40281928-ED7466CD-F0A6-4D6A-89B4-DA9084865759Q40306743-73E3DDCB-39AC-4B30-A403-8170E64BABB3
P2860
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Inhibition of wild-type and mu ...... hibitor: implications for CML.
@ast
Inhibition of wild-type and mu ...... hibitor: implications for CML.
@en
Inhibition of wild-type and mu ...... hibitor: implications for CML.
@nl
type
label
Inhibition of wild-type and mu ...... hibitor: implications for CML.
@ast
Inhibition of wild-type and mu ...... hibitor: implications for CML.
@en
Inhibition of wild-type and mu ...... hibitor: implications for CML.
@nl
prefLabel
Inhibition of wild-type and mu ...... hibitor: implications for CML.
@ast
Inhibition of wild-type and mu ...... hibitor: implications for CML.
@en
Inhibition of wild-type and mu ...... hibitor: implications for CML.
@nl
P2093
P1433
P1476
Inhibition of wild-type and mu ...... hibitor: implications for CML.
@en
P2093
Chester A Metcalf
David Dalgarno
Eric P Stoffregen
Jeffrey A Keats
Michael W Deininger
Omar M Abdullah
Raji Sundaramoorthi
Regine S Bohacek
Roy Pollock
P304
P356
10.1182/BLOOD-2004-05-1851
P407
P577
2004-07-15T00:00:00Z